Report Library
All Reports
Inflammatory Bowel Disease (IBD) KOL Interview - US, Midwest
February 22, 2024
In this discussion with a US-based KOL, we dive into in-depth opinions on the approved agents and late-stage pipeline drugs in the IBD market. The KOL discusses the current treatment approaches and the future of Crohn’s disease and ulcerative colitis treatment. The KOL also discusses the launches of biosimilars and pipeline therapies which show promise in the indication.
This interview was conducted on 9 November 2023.
If you are a KOL Insight Subscriber, you may also access the interview from our KOL Insight portal.
Biomedtracker's KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900.
For our disclosures, please read the Biomedtracker Research Standards.
Indications Covered: |
Crohn's Disease
Inflammatory Bowel Disease (IBD) Ulcerative Colitis (UC) |
Additional Resources: